 |
Previous Article | Next Article 
Volume 17, Number 2,
Issue of January 15, 1997
pp. 796-803
Copyright ©1997 Society for Neuroscience
Increased Probability of GABA Release during Withdrawal from
Morphine
Antonello Bonci and
John T. Williams
The Vollum Institute, L474, Oregon Health Sciences University,
Portland, Oregon 97201
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
Opioid receptors located on interneurons in the ventral tegmental
area (VTA) inhibit GABAA-mediated synaptic transmission to
dopamine projection neurons. The resulting disinhibition of dopamine
cells in the VTA is thought to play a pivotal role in drug abuse;
however, little is known about how this GABAA synapse is
affected after chronic morphine treatment. The regulation of GABA
release during acute withdrawal from morphine was studied in slices
from animals treated for 6-7 d with morphine. Slices containing the
VTA were prepared and maintained in morphine-free solutions, and
GABAA IPSCs were recorded from dopamine cells. The
amplitude of evoked IPSCs and the frequency of spontaneous miniature
IPSCs measured in slices from morphine-treated guinea pigs were greater
than placebo-treated controls. In addition, activation of adenylyl
cyclase, with forskolin, and cAMP-dependent protein kinase, with
Sp-cAMPS, caused a larger increase in IPSCs in slices from
morphine-treated animals. Conversely, the kinase inhibitors
staurosporine and Rp-CPT-cAMPS decreased GABA IPSCs to a greater extent
after drug treatment. The results indicate that the probability of GABA
release was increased during withdrawal from chronic morphine treatment
and that this effect resulted from an upregulation of the
cAMP-dependent cascade. Increased transmitter release from
opioid-sensitive synapses during acute withdrawal may be one adaptive
mechanism that results from prolonged morphine treatment.
Key words:
ventral tegmental area;
dopamine;
cAMP;
A-kinase;
GABAA;
tolerance
INTRODUCTION
Chronic use of opioids results in tolerance to and
dependence on the drug. One of the most widely accepted mechanisms for the cellular basis of tolerance is an uncoupling of the opioid receptor
from the effector so that a greater receptor occupancy is required to
obtain a given response (Law et al., 1982 ; Chavkin and Goldstein, 1984 ;
Puttfarcken et al., 1988 ). Dependence is defined by a number of
abnormal responses after the abrupt withdrawal of drug (Johnson and
Flemming, 1989 ). The expression of dependence, or withdrawal, is
thought to result from the development of adaptive changes that occur
in the continued presence of agonist. The first adaptive response to be
recognized at the cellular level was an upregulation of adenylyl
cyclase (Sharma et al., 1975 ). Acutely, opioids inhibit the activity of
adenylyl cyclase. However, in the continued presence of agonist the
inhibition declined until the activity in the presence of agonist was
not different from control. Adenylyl cyclase activity measured after
the removal of opioid was increased above control. This rebound
increase was thought to represent a cellular expression of opioid
withdrawal. Much of what is known about the cellular basis for
tolerance and dependence to opioids has come from studies on the opioid
regulation of adenylyl cyclase in cell lines, although the cellular
basis for the upregulation is not understood (Sharma et al., 1975 ; Law et al., 1982 ; Puttfarcken et al., 1988 ).
The electrophysiological approach has been used successfully to
demonstrate tolerance to opioids; however, the cellular expression of
withdrawal has been much more difficult to identify (Christie et al.,
1987 ; Wimpey et al., 1989 ; Kennedy and Henderson, 1991 , 1992 ). In the
locus coeruleus (LC), for example, tolerance to the opioid-induced
inhibition in firing and the associated increase in potassium
conductance has been demonstrated both in vivo and in
vitro (Aghajanian, 1978 ; Christie et al., 1987 ). After withdrawal, however, the increased firing rate of LC neurons resulted primarily from augmented excitatory afferent drive (Tung et al., 1990 ; Akaoka and
Aston-Jones, 1991 ).
The ventral tegmental area (VTA) is part of the endogenous reward
circuit that is thought to be activated by many drugs of abuse,
including opioids (Bozarth and Wise, 1981 ; Wise and Rompre, 1989 ).
Within the VTA, GABAA-mediated IPSPs recorded in dopamine cells were thought to arise from excitation of local interneurons (Johnson and North, 1992a ). As has been observed in many areas of the
CNS, opioids directly inhibit these interneurons through activation of
a potassium conductance (Nicoll et al., 1980 ; Madison and Nicoll, 1988 ;
Wimpey and Chavkin, 1991 ; Johnson and North, 1992a ). Thus, acute
activation of opioid receptors within the VTA indirectly increased the
activity of dopamine cells by removing GABA-mediated inhibition
(Gysling and Wang, 1983 ). The purpose this study was to examine the
GABAA IPSC during acute withdrawal from morphine and to
identify potential second-messenger pathways that mediate altered
function.
MATERIALS AND METHODS
Whole-cell recordings of membrane current were made from
dopamine neurons in horizontal slices of guinea pig midbrain.
Preparation of slices has been described previously (Cameron and
Williams, 1994 ). Briefly, guinea pigs (300-400 gm) were anesthetized
with halothane and killed. The midbrain was sliced (250 µm) in the horizontal plane using a vibratome. Slices (up to 3) containing the VTA
were stored before being placed in the recording chamber and superfused
(1.5 ml/min) with warmed (35°C) Krebs/bicarbonate buffer containing
the following (in mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, MgCl2 1.2, CaCl2 2.4, glucose 11, NaHCO3 21.4, saturated with 95% O2/5% CO2. Cells were visualized
using an upright microscope with infrared illumination and recordings
were made with whole-cell electrodes containing the following
(mM): KCl 128, NaCl 20, MgCl2 1, EGTA 1, CaCl2 0.3, Mg-ATP 2, GTP 0.25, buffered with HEPES 10, pH
7.3. Electrode resistance was 2-4 M , and acceptable access resistance was <15 M , which was monitored periodically with
repetitive 10 mV steps (20 msec duration) from a holding potential of
60 mV. Series resistance compensation of ~80% was used during the entire experiment. Identification of dopamine cells was made based on
the physiological properties, including a large
Ih-current (previously described by Johnson and
North, 1992b ). A monopolar glass stimulating electrode was placed near
(30-100 µm) the cell body. Neurons were voltage-clamped at a
membrane potential of 60 mV. Spontaneous IPSCs were recorded in the
presence of TTX (300 nM) using PClamp (60 sweeps for each
condition, 1 sec/sweep), and miniature IPSC (mIPSC) amplitude was
measured for each individual IPSC using Axograph 3.0. To determine
accurately the IPSC amplitude, only IPSCs that were >8 pA were
accepted for analysis. Results were plotted as cumulative amplitude and
frequency histograms, and the effects of drugs were tested using the
Komolgrov-Smirnov statistical method (Cohen et al., 1992 );
p < 0.05 was taken as indicating statistical
significance.
Drugs were applied in known concentrations to the superfusion medium.
In experiments examining the GABAA synaptic potential, the
superfusion medium contained 2-amino-5-phosphonopentanoic acid (AP5;
100 µM), 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline (CNQX;
10 µM), strychnine (1 µM), and eticlopride
(100 nM) to block NMDA, AMPA, glycine, and dopamine
D2-mediated synaptic currents, respectively. There was no
effect of this solution on the holding current of the dopamine cells
used in the present study. The same observation has been reported using
this mixture of antagonists in guinea pig (Bonci and Williams, 1996 )
and rat VTA (Johnson and North, 1992b ; Johnson et al., 1992 ). AP5 and
picrotoxin were obtained from Sigma (St. Louis, MO). CNQX and
eticlopride were obtained from Research Biochemicals (Natick, MA).
Morphine (75 mg morphine/pellet obtained from National Institute on
Drug Abuse) or placebo pellets (5 total) were implanted subcutaneously
in anesthetized guinea pigs, one on day 1 and two on days 3 and 5. Experiments were carried out on days 6 and 7.
Results in the text and figures were presented as the mean ± SEM.
Results between groups were compared using an unpaired t test; p < 0.05 was taken as indicating statistical
significance.
RESULTS
Whole-cell recordings were made from dopamine cells in guinea pig
brain slices that were identified as cells with a prominent hyperpolarization-induced inward current (Ih)
when the holding potential was stepped from 60 mV to more negative
potentials (Johnson and North, 1992b ). Electrically evoked
GABAA IPSCs were inward at a membrane potential of 60 mV
and were completely blocked by picrotoxin (100 µM). In
all experiments, other synaptic currents were blocked with receptor
antagonists (see Materials and Methods). Slices from both placebo- and
morphine-treated animals were prepared and maintained in morphine-free
solution. The opioid agonist normorphine depressed the amplitude of
these GABAA-mediated IPSCs (Fig.
1A). In control, the EC50
of normorphine was 180 ± 83 nM and the peak inhibition was 83 ± 8% (n = 4). After chronic
morphine treatment, the normorphine-induced inhibition of IPSCs had an
EC50 of 380 ± 60 nM and the peak
inhibition was 70 ± 3% (n = 4). These initial experiments demonstrate that this commonly used treatment protocol was
sufficient to cause some tolerance to opioids in the VTA.
Fig. 1.
IPSCs from morphine-treated animals show
paired-pulse depression, unlike those from controls, which show
paired-pulse facilitation. A, Recording of
GABAA-mediated IPSCs from a control slice using the
paired-pulse protocol (left trace). Normorphine (1 µM) depressed the IPSC (middle trace), and
that inhibition was reversed by the addition of naloxone to the
normorphine-containing solution (right trace).
B, Examples from three different cells in slices from both placebo- and morphine-treated animals. C,
Cumulative results showing the distribution of paired-pulse ratio for
many cells in slices from placebo (n = 41)- and
morphine (n = 41)-withdrawn slices.
D, The paired-pulse ratio is independent of the stimulus strength. These results are the average from four cells in each group
of animals.
[View Larger Version of this Image (30K GIF file)]
Morphine withdrawal augments GABA release
All experiments were carried out in morphine-free solutions at
least 1 hr and as long as 8 hr after preparation of the brain slice.
Characterization of GABA release after withdrawal from chronic morphine
treatment was studied using two methods. The first method used a
paired-pulse protocol, in which two stimuli were applied at an interval
of 50 msec. In slices from the placebo-treated group, the second pulse
evoked an IPSC that was generally larger than the first pulse (Fig.
1B). That is, facilitation of transmitter release was
observed in 78% of cells in control (s2/s1 = 1.18 ± 0.07, n = 41). In morphine-withdrawn slices, the second
stimulus evoked a smaller IPSC in 80% of cells tested (s2/s1 = 0.60 ± 0.14, n = 41). Thus, during morphine
withdrawal the paired-pulse protocol resulted in depression. The
numbers of cells showing facilitation and depression using the
paired-pulse protocol are illustrated in Figure 1C and
indicate that depression was observed most often during morphine
withdrawal. Facilitation or depression was not dependent on the size of
the initial IPSC (Fig. 1B) and was not affected by
changing the stimulus intensity (Fig. 1D).
Manipulations that increase transmitter release in many sites have been
found to result in a shift in the paired-pulse ratio toward depression (Mennerick and Zorumski, 1995 ; Salin et al., 1996 ). The present results
suggest that the probability of GABA release was augmented during
morphine withdrawal. Paired-pulse depression during morphine withdrawal
was relatively persistent, because it was observed in slices as early
as 1 hr and up to 8 hr after the slice was placed in morphine-free
solution.
One possible explanation for the depression found during morphine
withdrawal was that the GABAA receptors may be more likely to desensitize. Direct application of GABA using iontophoresis was used
as a postsynaptic control to test this possibility. GABA (50-150 nA)
was applied at a distance of 3-10 µm from the dopamine cell body.
Two pulses of GABA (10-20 msec) were applied 100 msec apart. The
amplitude of the inward current among different cells ranged from 27 pA
to 4 nA, and the duration ranged from 50 to 100 msec. There was no
consistent difference between the amplitude of the first and second
pulses in slices from morphine-treated animals (n = 5, data not shown).
The frequency and amplitude of spontaneous mIPSCs (in 500 nM TTX) comprised the second method used to identify
altered regulation of GABA release during morphine withdrawal. The rate
of spontaneous mIPSCs was significantly greater in morphine-withdrawn
slices [control, 2.4 ± 1.3 Hz (n = 8);
morphine-withdrawn, 9.3 ± 2.8 Hz (n = 7, p < 0.05)]. There was no significant difference in the amplitude distribution of spontaneous mIPSCs in the two groups. The
mean amplitude of spontaneous mIPSCs was 36.4 ± 2.8 pA in control
and 35.6 ± 4.1 in morphine-withdrawn slices. Therefore, both the
paired-pulse protocol and the increase in frequency of spontaneous
events suggested that the probability of GABA release in the VTA was
increased during withdrawal from morphine.
It was possible that the difference in GABA release between the two
groups of animals resulted indirectly from activation of presynaptic
receptors in response to a second transmitter. Potential candidates
include GABA itself, adenosine, and 5-HT, all of which are present and
have been shown to cause potent presynaptic inhibition of GABA release
(Johnson et al., 1992 ; Wu et al., 1995 ). The amplitude of the IPSC (S1)
was measured in the presence of both the GABAB receptor
antagonist CGP35348 (100 µM) and the A1 antagonist DPCPX
(1 µM). In DPCPX, the amplitude of the IPSC was increased
in both groups of animals to the same extent [11 ± 7.8% in
control (n = 7) and 12.3 ± 7.3 in
morphine-withdrawn slices (n = 7)]. The IPSC was not
affected by CGP35348 (control, n = 3;
morphine-withdrawn, n = 4). Although 5-HT caused a
potent presynaptic inhibition of the GABAB IPSP, it had no
effect on the GABAA IPSP in rat (Johnson et al., 1992 ).
There was no effect of the nonselective 5-HT1 agonist 5-CT
(1 µM) on the GABAA IPSC in slices from
control and morphine-treated guinea pigs (n = 5 for
each group). Because the amplitude of the IPSC was not selectively
affected by any of these manipulations in cells from morphine-withdrawn
slices, the results suggest that the increase in GABAA IPSC
observed in morphine-treated animals did not result from altered
sensitivity to endogenous adenosine, GABA, or 5-HT.
cAMP-dependent modulation of GABA release
It has been known for many years that chronic morphine treatment
augments adenylyl cyclase activity in cell lines and various parts of
the CNS (Johnson and Flemming, 1989 ). In addition, forskolin stimulation of adenylyl cyclase has been shown to increase
release of both GABA and glutamate in a variety of preparations
including the VTA (Cameron and Williams, 1993 ; Rosenmund et al., 1994 ;
Bonci and Williams, 1996 ; Salin et al., 1996 ). Forskolin produced a concentration-dependent increase in the amplitude of the
GABAA IPSC in both control and morphine-withdrawn slices
(Fig. 2). The forskolin-induced increase in
morphine-withdrawn slices was significantly larger and longer lasting
than that in controls (Fig. 2B,C).
The sensitivity to forskolin was not changed, but the maximum effect was increased (EC50 1.8 µM in control, 1.5 µM in withdrawn slices, maximum augmentation
66% in control and 125% in withdrawn slices; Fig. 2C). The
inactive analog of forskolin, dideoxyforskolin (10 µM),
had no significant effect on the IPSC (percent change from control,
4.3 ± 5.1% in placebo, 5.1 ± 6.2 in morphine-withdrawn, n = 4 cells each).
Fig. 2.
Forskolin augments the IPSC. This augmentation is
significantly larger in morphine-withdrawn slices than in the placebo
controls (p < 0.05). A,
Examples of experiments from placebo- and morphine-treated animals.
B, The amplitude of the first IPSC is plotted as a
function of time in cells from placebo (open circles)-
and morphine (solid circles)-withdrawn slices. Results
are from four slices for each group. Forskolin (10 µM)
increased the amplitude of the IPSC to a greater extent and for a more
prolonged period in morphine-withdrawn slices than in controls.
C, The concentration response to forskolin. The
amplitude of the first IPSC in the paired-pulse protocol is plotted as
a function of the concentration of forskolin. The amplitude was
normalized against the mean of the first 10 IPSCs for each cell.
Results were obtained from four cells from four different animals in
each group. The data were fit with a least-squares regression from a
logistic equation and gave estimates of the EC50 and
maximum effect of forskolin of 1.8 µM and 66% increase in control and 1.5 µM and 125% increase in
morphine-withdrawn slices.
[View Larger Version of this Image (23K GIF file)]
The frequency of spontaneous mIPSCs was also significantly increased by
forskolin (10 µM) in morphine-withdrawn slices (from 9.3 ± 2.8 to 23.6 ± 3.5 Hz, n = 7) animals
as compared to controls (2.4 ± 1.3 to 3.2 ± 1.2 Hz,
n = 8; Fig. 3). There was no significant difference in the amplitude of the mIPSCs in the absence and presence of forskolin in slices from either group of animals. In slices from
control animals the mean amplitude was 36.4 ± 2.8 pA in control and 37.9 ± 4.3 pA in forskolin (10 µM), and in
slices from morphine-withdrawn animals the mean amplitude was 35.6 ± 4.1 pA in control and 34.4 ± 3.2 pA in forskolin. An
upregulation of adenylyl cyclase could account for the increase in
probability of GABA release as determined by the depression of the
paired-pulse ratio and the increase in spontaneous mIPSCs in
morphine-withdrawn slices.
Fig. 3.
Forskolin increased the frequency of spontaneous
mIPSCs to a greater extent in morphine-withdrawn slices than in placebo
controls. A, Experiment from a cell in a slice from a
control animal. Top traces show the occurrence of
spontaneous IPSCs in control (left) and after
superfusion with forskolin (10 µM, right).
The three plots below the traces show an amplitude histogram
(left), a cumulative probability plot of the amplitude
(middle), and a cumulative probability plot of the
frequency of spontaneous IPSCs from the same cell shown above. In this
particular cell, forskolin had little effect on the rate and amplitude
of the spontaneous IPSCs. B, Illustration of the same
experiment in a cell recorded in a slice taken from a morphine-treated
animal. The initial rate of activity was higher, and forskolin induced
a significant increase in the rate of spontaneous IPSCs
(p < 0.05). All experiments were carried
out in the presence of TTX (500 nM), CNQX (10 µM), APV (100 µM), strychnine (1 µM), and eticlopride (100 nM).
[View Larger Version of this Image (38K GIF file)]
Kinase-dependent modulation of GABA release
Superfusion with the cAMP analog Sp-cAMPS (100 µM,
15 min) had little or no effect on the amplitude of the IPSC (9.2 ± 3.7%, n = 3; Fig. 4); however, the
same protocol caused a significant augmentation in the IPSC amplitude
in withdrawn slices (46 ± 11%, n = 3, p < 0.05; Fig. 4). This experiment suggested that the
forskolin-induced increase in GABAA IPSCs may involve
cAMP-dependent kinase.
Fig. 4.
The cAMP analog Sp-cAMPS is more effective in
increasing the IPSC in slices from morphine-withdrawn slices than
placebo controls. The amplitude of the electrically evoked IPSC is
plotted as a function of time. A, Top,
Example of one experiment in a slice taken from a control animal. The
cAMP analog Sp-cAMPS (100 µM) has no effect on the
amplitude of the IPSC, whereas a low concentration of forskolin (1 µM) increased the amplitude of the IPSC.
Bottom, Average of four such experiments in slices taken
from four different animals. The average amplitude of IPSCs over the
first 5 min was used to normalize the data. B,
Top, An experiment in a single cell taken from a
morphine-treated animal. In this case, cAMP analog Sp-cAMPS caused an
increase in the IPSC that was about the same as that induced by
forskolin. Bottom, Normalized and averaged results from
four experiments.
[View Larger Version of this Image (30K GIF file)]
The nonselective kinase inhibitor staurosporine (300 nM)
caused a decrease of 45 ± 4.3% (n = 4) in the
amplitude of the IPSC in morphine-withdrawn slices. This inhibition was
larger than that found in slices from control animals (26 ± 4.3%
of control, n = 4, p < 0.05; Fig.
5). The ratio of IPSC amplitudes found using the
paired-pulse protocol was not changed by staurosporine in control
(1.41 ± 0.1 in control to 1.42 ± 0.2 in staurosporine, n = 4) but was increased in withdrawn slices (0.58 ± 0.07 in control, 1.66 ± 0.2 in staurosporine). In addition,
the frequency but not the amplitude of spontaneous IPSCs was also
decreased by staurosporine, an effect that was significantly greater in
withdrawn slices (from 8.9 ± 1.8 Hz in control to 2.7 ± 0.8 Hz in staurosporine, n = 6) than in controls (from
2.1 ± 0.3 Hz in control to 2.0 ± 0.4 Hz in staurosporine,
n = 6; Fig. 6). Finally, the
forskolin-induced increase in IPSCs was blocked by pretreatment with
staurosporine (Fig. 5).
Fig. 5.
The protein kinase inhibitors staurosporine
(A, 300 nM) and Rp-CPT-cAMPS
(B, 100 µM) decreased the IPSC in slices
from both placebo- and morphine-treated animals. The inhibition is
greater in morphine-withdrawn slices. In all plots, the IPSC amplitudes were normalized to the average determined over the first 5 min of the
experiment. Plots on the left are from control animals (Placebo), and plots on the right
are from morphine-treated animals (Withdrawn).
A, A low concentration of forskolin (1 µM)
increased the amplitude of the IPSC, and staurosporine decreased the
amplitude of the IPSC and blocked the forskolin-induced augmentation
(n = 4). The plot labeled Withdrawn
is the same experiment as shown at the left in slices
taken from four morphine-treated animals. The inhibition induced by
staurosporine is significantly larger than in controls
(p < 0.05). B, The cAMP
analog Rp-CPT-cAMPS, a cAMP-dependent kinase inhibitor, produced a
greater inhibition of the amplitude of IPSCs in slices from both
withdrawn slices than placebo controls (n = 4 for
each group; p < 0.05). The same protocol was used
as described for A.
[View Larger Version of this Image (36K GIF file)]
Fig. 6.
The frequency of mIPSCs is decreased by
staurosporine (300 nM). The decrease is greater in
morphine-withdrawn slices than in controls. A,
Experiment from a cell in a slice from a control animal. Top
traces show the occurrence of spontaneous IPSCs in control
(left) and after superfusion with staurosporine (300 nM, right). The three plots below the
traces show an amplitude histogram (left), a
cumulative probability plot of the amplitude (middle), and a cumulative probability plot of the frequency of spontaneous IPSCs
from the same cell shown above. Staurosporine had little effect on the rate and amplitude of the spontaneous IPSCs.
B, Illustration of the same experiment in a cell from a
morphine-withdrawn slice. The initial rate of activity was higher, and
staurosporine induced a significant decrease in the rate of spontaneous
IPSCs (p < 0.05).
[View Larger Version of this Image (35K GIF file)]
To characterize further the kinase involved in the regulation of GABA
release, Rp-CPT-cAMPS, a relatively selective blocker of cAMP-dependent
kinase, was used. Superfusion with Rp-CPT-cAMPS (100 µM)
significantly reduced the amplitude of the IPSC
(p < 0.05; Fig. 5), blocked the effect of
forskolin (Fig. 5), and caused a shift of the paired-pulse ratio toward
facilitation in morphine-withdrawn slices (s2/s1 from 0.6 ± 0.2 to 1.25 ± 0.2, n = 3). The same protocol had no
effect in slices from control animals (s2/s1 from 1.41 ± 0.03 to
1.42 ± 0.1, n = 3). These observations suggest
that the activity of cAMP-dependent kinase was higher in
morphine-withdrawn slices from drug-treated animals than in controls
and that the increased activity was responsible for the augmented GABA
release.
The augmentation of IPSCs induced by phorbol dibutyrate (PDBU; 300 nM), a phorbol ester, was examined in slices from control and morphine-treated animals as a test for the selectivity of the
cAMP-dependent augmentation of GABA release. Although PDBU increased
the amplitude of the IPSC in both groups [control 38.5 ± 4.3%
(n = 4), morphine 44.8 ± 6.7% (n = 3)], the augmentation was the same in each. A small depression of
the paired-pulse ratio (s2/s1) was caused by PDBU in each group
[control from 1.39 ± 0.1 to 0.9 ± 0.1 (n = 4), morphine-withdrawn from 0.6 ± 0.18 to 0.55 ± 0.04 (n = 3)]. Thus, it appeared that the augmentation of
transmitter release during morphine withdrawal may be mediated selectively through a cAMP-dependent pathway.
Experiments aimed at further identification of sites in the cAMP
cascade that were affected by morphine withdrawal were inconclusive. The adenylyl cyclase inhibitor SQ22356 (300 µM to 1 mM) was tested in an attempt to determine whether the basal
level of adenylyl cyclase activity was different in the two groups of
tissues. Although this compound caused an initial depression of the
IPSC, continued application resulted in a large increase in the IPSC,
such that the result was not interpretable. Initial experiments with
the nonselective phosphatase inhibitor tautomycin (100 nM)
were carried out to determine the role of phosphatases. Tautomycin
caused a transient augmentation of the IPSC followed by total
suppression, limiting interpretation of the results.
DISCUSSION
Morphine decreased the amplitude of the GABAA-mediated
IPSC in the VTA. After chronic treatment with morphine, there was some tolerance to opioids; however, the ability of opioids to inhibit release was maintained. The results of the present study demonstrate that during the initial period after withdrawal from prolonged morphine
exposure an upregulation of the adenylyl cyclase cascade resulted in an
increase in the probability of GABA release from terminals that mediate
GABAA IPSCs. This may result from an adaptive process at a
point beyond the opioid receptor because all experiments were carried
out in the absence of morphine. The persistence of the augmented
release after withdrawal of morphine for periods of up to 8 hr also
suggests that this adaptive mechanism was not dependent on opioid
receptor activation. It is important to determine how long the
augmented release persists because the release of GABA acting at
GABAB receptors was depressed 1 week after termination of
morphine treatment (Bonci and Williams, 1996 ). Our working hypothesis
is that the GABAA- and GABAB-mediated synaptic
inhibition results from separate sets of terminals. The augmented
GABAA-mediated inhibition described here may be a measure
of acute withdrawal from opioids that is relatively short-lived (1-3
d). The depression of GABAB-mediated inhibition, however,
is a long-term effect of withdrawal from chronic drug treatment that is
either not present or occluded by the augmented GABAA tone
early in withdrawal. In fact, during acute withdrawal from morphine
there may be diffusion of GABA between terminals mediating the two
synaptic events, as has been reported under certain conditions in the
hippocampus (Isaacson et al., 1993 ).
Upregulation of adenylyl cyclase/cAMP-dependent pathway
The present observations are consistent with reports of an
increased activity of adenylyl cyclase and cAMP-dependent protein kinase during acute withdrawal from chronic morphine treatment in cell
lines and in several brain areas (Sharma et al., 1975 ; Nestler and
Tallman, 1988 ) (for review, see Johnson and Flemming, 1989 ; Nestler et
al., 1993 ). Although biochemical experiments specifically in the VTA
have not demonstrated a rise in cyclase activity after chronic morphine
treatment, the heterogeneity of cell types in the VTA limits the
interpretation of negative data (Terwilliger et al., 1991 ). The present
study focused on a synapse known to be opioid-sensitive such that a
localized upregulation of the cAMP system in a small portion of neurons
and/or terminals could be detected.
There were two primary observations that indicate an upregulation of
the cAMP-dependent pathway after chronic morphine treatment. The first
was that forskolin caused a significantly larger increase in
GABAA IPSCs in slices from morphine-treated animals than
controls. This effect was mediated by adenylyl cyclase because
dideoxyforskolin, an inactive analog that does not activate adenylyl
cyclase, did not have any effect. The concentration response to
forskolin resulted in an increase in the maximum response rather than a
change in the EC50. The augmented maximum effect of
forskolin could result from a number of mechanisms, including an
increase in the Vmax of adenylyl cyclase, a
decline in cAMP-dependent phosphodiesterase activity, or an
upregulation of downstream cAMP-dependent processes. There is evidence
in the literature that all three mechanisms can occur in response to
chronic morphine treatment (Yu et al., 1990 ; Self and Nestler, 1995 ).
The increased sensitivity to cAMP during withdrawal seems selective as
suggested by the experiments with the protein kinase C activator PDBU.
Although PDBU increased the amplitude of GABAA IPSCs, the
increase was not different in slices from control and morphine-treated
animals.
The second observation was that agents that interact directly with
cAMP-dependent kinase had quantitatively different effects in
morphine-withdrawn slices. The stable cAMP analog Sp-cAMPS caused only
a small increase in the IPSC in control (9%) but had a significantly
greater effect in slices from morphine-treated animals (46%). This
experiment suggests that cAMP-dependent kinase activity was increased
during acute withdrawal. In addition, the results with the kinase
inhibitors Rp-CPT-cAMPS and staurosporine suggested that the basal
kinase activity was elevated in slices from morphine-treated animals.
Such an upregulation of basal and stimulated kinase activity after
chronic morphine treatment has been reported in cell lines and various
brain areas (Duman et al., 1988 ; Nestler and Tallman, 1988 ; Nestler et
al., 1993 ).
Morphine withdrawal
There are numerous examples of an increased firing rate after
withdrawal of opioids in experiments done in vivo (Fry et
al., 1980 ; Johnson and Duggan, 1981 ). The identification of cellular mechanisms of morphine withdrawal has proven difficult in brain slices
(Christie et al., 1987 ; Wimpey et al., 1989 ) and in cell lines (Kennedy
and Henderson, 1991 , 1992 ). That is, withdrawal from morphine has not
been observed to cause a rebound effect on either potassium or calcium
conductances. Recently, a subpopulation of neurons in the
periaqueductal gray (PAG) from morphine-dependent animals has been
observed to be strongly depolarized by the addition of naloxone to the
superfusion solution (Chieng and Christie, 1996 ). This depolarization
appeared to be a direct because it was not affected by a combination of
neurotransmitter receptor antagonists or tetrodotoxin. Although acute
activation of opioid receptors on neurons in the PAG has been shown to
increase potassium conductance (Chieng and Christie, 1994 ), the
depolarization induced by naloxone in tissue from morphine-dependent
animals resulted from a decrease in potassium conductance (which may be
a reversal of the effect of morphine contained in the superfusion
solution) and another unidentified mechanism.
Reports on the excitability of neurons in the LC during morphine
withdrawal were dependent on the conditions of the experiment. In
in vivo experiments, systemic injection of naloxone caused a
marked increase in firing rate in morphine-treated animals (10-fold) that was largely blocked by glutamate receptor antagonists (Tung et
al., 1990 ; Akaoka and Aston-Jones, 1991 ). In brain slices, the firing
rate of LC neurons from morphine-treated animals has been reported to
be unchanged (Andrade et al., 1983 ) or increased twofold over controls
(Kogan et al., 1992 ). An increased sensitivity of LC cells to cAMP
analogs after chronic morphine treatment was suggested to account for
the increased firing rate (Kogan et al., 1992 ); however, experiments
were not done after blockade of glutamate or other neurotransmitter
receptors. The combination of results obtained with in vivo
experiments and the increased probability of transmitter release from
opioid-sensitive terminals observed in the present study suggest that
an excitatory synaptic mechanism may be important during morphine
withdrawal.
Significance
Whereas the firing rate of dopamine cells in the VTA was increased
acutely by morphine in vivo (Gysling and Wang, 1983 ), during withdrawal from morphine, activity was profoundly decreased (Diana et
al., 1995). In addition, many of the signs and symptoms of morphine
withdrawal were attenuated by activation of D2 dopamine receptors in the nucleus accumbens, suggesting that dopamine tone was
decreased during withdrawal (Harris and Aston-Jones, 1994 ). We suggest
that the withdrawal inhibition of dopamine cell firing and decreased
dopamine tone in the nucleus accumbens results from augmented GABA
tone. Results with mIPSCs suggest that the expression of this form of
withdrawal occurred at the terminals of GABA interneurons. The
physiological consequences resulting from the link between the acute
effects of opioids and cAMP mechanisms has been difficult to
demonstrate; however, the interaction among transmitter release, cAMP
mechanisms, and chronic opioid treatment may prove to be a general
observation. Given the number of opioid-sensitive terminals, both
excitatory and inhibitory, the augmented transmitter release after
chronic morphine treatment has the potential for widespread consequences.
FOOTNOTES
Received Sept. 17, 1996; revised Oct. 29, 1996; accepted Oct. 31, 1996.
This work was supported by National Institutes of Health Grant DA08163.
We thank MacDonald Christie, Jeffrey Diamond, and Matthew Jones for
helpful discussions and comments.
Correspondence should be addressed to Dr. John T. Williams, The Vollum
Institute, L474, Oregon Health Sciences University, 3181 SW Sam Jackson
Park Road, Portland, OR 97201.
REFERENCES
-
Aghajanian GK
(1978)
Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine.
Nature
276:186-187 .
[Medline]
-
Akaoka H,
Aston-Jones G
(1991)
Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input.
J Neurosci
11:3830-3839 .
[Abstract]
-
Andrade R,
Vandermaelen CP,
Aghajanian GK
(1983)
Morphine tolerance and dependence in the locus coeruleus: single cell studies in brain slices.
Eur J Pharmacol
91:161-165 .
[Web of Science][Medline]
-
Bonci A,
Williams JT
(1996)
A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine.
Neuron
16:631-639 .
[Web of Science][Medline]
-
Bozarth MA,
Wise RA
(1981)
Intracranial self-administration of morphine into the ventral tegmental area in rats.
Life Sci
28:551-555 .
[Web of Science][Medline]
-
Cameron DL,
Williams JT
(1993)
Dopamine D1 receptors facilitate transmitter release.
Nature
366:344-347 .
[Medline]
-
Cameron DL,
Williams JT
(1994)
Cocaine inhibits GABA release in the VTA through endogenous 5-HT.
J Neurosci
14:6763-6767 .
[Abstract]
-
Chavkin C,
Goldstein A
(1984)
Opioid receptor reserve in normal and morphine-tolerant guinea pig ilium myenteric plexus.
Proc Natl Acad Sci USA
81:7253-7257 .
[Abstract/Free Full Text]
-
Chieng B,
Christie MJ
(1994)
Hyperpolarization by opioids acting on µ-receptors of a subpopulation of rat periaqueductal gray neurones in vitro.
Br J Pharmacol
113:121-128 .
[Web of Science][Medline]
-
Chieng B,
Christie MJ
(1996)
Local opioid withdrawal in rat single periaqueductal gray neurons in vitro.
J Neurosci
16:7128-7136 .
[Abstract/Free Full Text]
-
Christie MJ,
Williams JT,
North RA
(1987)
Cellular mechanisms of opioid tolerance: studies in single brain neurons.
Mol Pharmacol
32:633-638 .
[Abstract]
-
Cohen GA,
Doze VA,
Madison DV
(1992)
Opioid inhibition of GABA release from presynaptic terminal of rat hippocampal interneurons.
Neuron
9:325-335 .
[Web of Science][Medline]
-
Dianan M,
Pistis M,
Muntoni A,
Gessa G
(1995)
Profound decrease of mesolimbic dopaminergic neuronal activity in morphine-withdrawn rats.
J Pharmacol Exp Ther
272:781-785.
[Abstract/Free Full Text]
-
Duman R,
Tallman J,
Nestler E
(1988)
Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus.
J Pharmacol Exp Ther
246:1033-1039 .
[Abstract/Free Full Text]
-
Fry JP,
Herz A,
Zieglgansberger W
(1980)
A demonstration of naloxone-precipitated opiate withdrawal on single neurons in the tolerance/dependent rat brain.
Br J Pharmacol
68:585-592 .
[Web of Science][Medline]
-
Gysling K,
Wang RY
(1983)
Morphine-induced activation of A10 dopamine neurons in the rat.
Brain Res
277:119-127 .
[Web of Science][Medline]
-
Harris GC,
Aston-Jones G
(1994)
Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome.
Nature
371:155-157 .
[Medline]
-
Isaacson JS,
Solis JM,
Nicoll RA
(1993)
Local and diffuse synaptic actions of GABA in the hippocampus.
Neuron
10:165-175 .
[Web of Science][Medline]
-
Johnson SM,
Duggan AW
(1981)
Tolerance and dependence of dorsal horn neurones of the cat: the role of the opiate receptors of the substantia gelatinosa.
Neuropharmacology
20:1033-1038 .
[Web of Science][Medline]
-
Johnson SM,
Flemming W
(1989)
Mechanisms of cellular adaptive sensitivity changes: application to opioid tolerance and dependence.
Pharmacol Rev
41:435-488 .
[Web of Science][Medline]
-
Johnson SW,
North RA
(1992a)
Opioids excite dopamine neurons by hyperpolarization of local interneurons.
J Neurosci
12:483-488 .
[Abstract]
-
Johnson SW,
North RA
(1992b)
Two types of neurone in the rat ventral tegmental area and their synaptic inputs.
J Physiol (Lond)
450:455-468 .
[Abstract/Free Full Text]
-
Johnson SW,
Mercuri NB,
North RA
(1992)
5-Hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons.
J Neurosci
12:2000-2006 .
[Abstract]
-
Kennedy C,
Henderson G
(1991)
µ-Opioid receptor inhibition of calcium current: development of homologous tolerance in single SH-SY5Y cells after chronic exposure to morphine in vitro.
Mol Pharmacol
40:1000-1005 .
[Abstract]
-
Kennedy C,
Henderson G
(1992)
Chronic exposure to morphine does not induce dependence at the level of the calcium channel current in human SH-SY5Y cells.
Neuroscience
49:937-944 .
[Web of Science][Medline]
-
Kogan J,
Nestler E,
Aghajanian G
(1992)
Elevated basal firing rates and enhanced responses to 8Br-cAMP in locus coeruleus neurons in brain slices from opiate-dependent rats.
Eur J Pharmacol
211:47-53 .
[Web of Science][Medline]
-
Law PY,
Hom DS,
Loh HH
(1982)
Loss of opiate receptor activity in neuroblastoma × glioma NG108-15 hybrid cells after chronic opiate treatment: a multiple-step process.
Mol Pharmacol
22:1-4 .
[Abstract]
-
Madison DV,
Nicoll RA
(1988)
Enkephalin hyperpolarizes interneurones in the rat hippocampus.
J Physiol (Lond)
398:123-130 .
[Abstract/Free Full Text]
-
Mennerick S,
Zorumski CF
(1995)
Paired-pulse modulation of fast excitatory synaptic currents in microcultures of rat hippocampal neurons.
J Physiol (Lond)
488:85-101 .
[Abstract/Free Full Text]
-
Nestler E,
Tallman J
(1988)
Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus.
Mol Pharmacol
33:127-132 .
[Abstract]
-
Nestler EJ,
Hope BT,
Widnell KL
(1993)
Drug addiction: a model for the molecular basis of neural plasticity.
Neuron
11:995-1006 .
[Web of Science][Medline]
-
Nicoll RA,
Alger BE,
Jahr CE
(1980)
Enkephalin blocks inhibitory pathways in the vertebrate CNS.
Nature
287:22-25 .
[Medline]
-
Puttfarcken PS,
Werling LL,
Cox BM
(1988)
Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at µ opioid receptors.
Mol Pharmacol
33:520-527 .
[Abstract]
-
Rosenmund C,
Carr DW,
Bergeson SE,
Nilaver G,
Scott JD,
Westbrook GL
(1994)
Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons.
Nature
368:853-856 .
[Medline]
-
Salin PA,
Malenka RC,
Nicoll RA
(1996)
Cyclic AMP mediates a presynaptic form of LTP at cerebellar parallel fiber synapses.
Neuron
16:797-803 .
[Web of Science][Medline]
-
Self DW,
Nestler EJ
(1995)
Molecular mechanisms of drug reinforcement and addiction.
Annu Rev Neurosci
18:46395.
-
Sharma SK,
Klee WA,
Nirenberg M
(1975)
Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance.
Proc Natl Acad Sci USA
72:3092-3096 .
[Abstract/Free Full Text]
-
Terwilliger RZ,
Beitner-Johnson D,
Sevarino KA,
Crain SM,
Nestler EJ
(1991)
A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function.
Brain Res
548:100-110 .
[Web of Science][Medline]
-
Tung CS,
Grenhoff J,
Svensson TH
(1990)
Morphine withdrawal responses of rat locus coeruleus neurons are blocked by an excitatory amino-acid antagonist.
Acta Physiol Scand
138:581-582 .
[Web of Science][Medline]
-
Wimpey TL,
Chavkin C
(1991)
Opioids activate both an inward rectifier and a novel voltage-gated potassium conductance in the hippocampal formation.
Neuron
6:281-289 .
[Web of Science][Medline]
-
Wimpey TL,
Opheim KE,
Chavkin C
(1989)
Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
J Pharmacol Exp Ther
251:405-411 .
[Abstract/Free Full Text]
-
Wise RA,
Rompre PP
(1989)
Brain DA and reward.
Annu Rev Psychol
40:191-225 .
[Web of Science][Medline]
-
Wu Y,
Mercuri NB,
Johnson SW
(1995)
Presynaptic inhibition of
-aminobutyric acid-B-mediated synaptic current by adenosine recorded in vitro in midbrain dopamine neurons.
J Pharmacol Exp Ther
273:576-581 .
[Abstract/Free Full Text]
-
Yu VC,
Eiger S,
Duan DS,
Lameh J,
Sadee W
(1990)
Regulation of cyclic AMP by the µ-opioid receptor in human neuroblastoma SH-SY5Y cells.
J Neurochem
55:1390-1396 .
[Web of Science][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
C. H. Yang, B. H. Lee, and S. H. Sohn
A Possible Mechanism Underlying the Effectiveness of Acupuncture in the Treatment of Drug Addiction
Evid. Based Complement. Altern. Med.,
September 1, 2008;
5(3):
257 - 266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Li, M. L. Lee, M. R. Bruchas, G. C. Chan, D. R. Storm, and C. Chavkin
Calmodulin-Stimulated Adenylyl Cyclase Gene Deletion Affects Morphine Responses
Mol. Pharmacol.,
November 1, 2006;
70(5):
1742 - 1749.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tonini, S. Ciardo, M. Cerovic, T. Rubino, D. Parolaro, M. Mazzanti, and R. Zippel
ERK-Dependent Modulation of Cerebellar Synaptic Plasticity after Chronic {Delta}9-Tetrahydrocannabinol Exposure
J. Neurosci.,
May 24, 2006;
26(21):
5810 - 5818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. P. Ford, G. P. Mark, and J. T. Williams
Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location.
J. Neurosci.,
March 8, 2006;
26(10):
2788 - 2797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Zuo
The Role of Opioid Receptor Internalization and {beta}-Arrestins in the Development of Opioid Tolerance
Anesth. Analg.,
September 1, 2005;
101(3):
728 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. McClung, E. J. Nestler, and V. Zachariou
Regulation of Gene Expression by Chronic Morphine and Morphine Withdrawal in the Locus Ceruleus and Ventral Tegmental Area
J. Neurosci.,
June 22, 2005;
25(25):
6005 - 6015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Bie, Y. Peng, Y. Zhang, and Z. Z. Pan
cAMP-Mediated Mechanisms for Pain Sensitization during Opioid Withdrawal
J. Neurosci.,
April 13, 2005;
25(15):
3824 - 3832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Frenois, L. Stinus, F. Di Blasi, M. Cador, and C. Le Moine
A Specific Limbic Circuit Underlies Opiate Withdrawal Memories
J. Neurosci.,
February 9, 2005;
25(6):
1366 - 1374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Roberto, S. G. Madamba, D. G. Stouffer, L. H. Parsons, and G. R. Siggins
Increased GABA Release in the Central Amygdala of Ethanol-Dependent Rats
J. Neurosci.,
November 10, 2004;
24(45):
10159 - 10166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-H. Ye, F. Wang, K. Krnjevic, W. Wang, Z.-G. Xiong, and J. Zhang
Presynaptic Glycine Receptors on GABAergic Terminals Facilitate Discharge of Dopaminergic Neurons in Ventral Tegmental Area
J. Neurosci.,
October 13, 2004;
24(41):
8961 - 8974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Dumont and J. T. Williams
Noradrenaline Triggers GABAA Inhibition of Bed Nucleus of the Stria Terminalis Neurons Projecting to the Ventral Tegmental Area
J. Neurosci.,
September 22, 2004;
24(38):
8198 - 8204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nagai, K. Yamada, M. Yoshimura, K. Ishikawa, Y. Miyamoto, K. Hashimoto, Y. Noda, A. Nitta, and T. Nabeshima
From The Cover: The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release
PNAS,
March 9, 2004;
101(10):
3650 - 3655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Roberto, P. Schweitzer, S. G. Madamba, D. G. Stouffer, L. H. Parsons, and G. R. Siggins
Acute and Chronic Ethanol Alter Glutamatergic Transmission in Rat Central Amygdala: an In Vitro and In Vivo Analysis
J. Neurosci.,
February 18, 2004;
24(7):
1594 - 1603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Melis, M. Pistis, S. Perra, A. L. Muntoni, G. Pillolla, and G. L. Gessa
Endocannabinoids Mediate Presynaptic Inhibition of Glutamatergic Transmission in Rat Ventral Tegmental Area Dopamine Neurons through Activation of CB1 Receptors
J. Neurosci.,
January 7, 2004;
24(1):
53 - 62.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Bolanos, L. I. Perrotti, S. Edwards, A. J. Eisch, M. Barrot, V. G. Olson, D. S. Russell, R. L. Neve, and E. J. Nestler
Phospholipase C{gamma} in Distinct Regions of the Ventral Tegmental Area Differentially Modulates Mood-Related Behaviors
J. Neurosci.,
August 20, 2003;
23(20):
7569 - 7576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Harrison, R. G. Allen, M. J. Pellegrino, J. T. Williams, and O. J. Manzoni
Chronic Morphine Treatment Alters Endogenous Opioid Control of Hippocampal Mossy Fiber Synaptic Transmission
J Neurophysiol,
May 1, 2002;
87(5):
2464 - 2470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Z. Shaw-Lutchman, M. Barrot, T. Wallace, L. Gilden, V. Zachariou, S. Impey, R. S. Duman, D. Storm, and E. J. Nestler
Regional and Cellular Mapping of cAMP Response Element-Mediated Transcription during Naltrexone-Precipitated Morphine Withdrawal
J. Neurosci.,
May 1, 2002;
22(9):
3663 - 3672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Melis, R. Camarini, M. A. Ungless, and A. Bonci
Long-Lasting Potentiation of GABAergic Synapses in Dopamine Neurons after a Single In Vivo Ethanol Exposure
J. Neurosci.,
March 15, 2002;
22(6):
2074 - 2082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pu, G.-B. Bao, N.-J. Xu, L. Ma, and G. Pei
Hippocampal Long-Term Potentiation Is Reduced by Chronic Opiate Treatment and Can Be Restored by Re-Exposure to Opiates
J. Neurosci.,
March 1, 2002;
22(5):
1914 - 1921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Wetherington and N. A. Lambert
Differential Desensitization of Responses Mediated by Presynaptic and Postsynaptic A1 Adenosine Receptors
J. Neurosci.,
February 15, 2002;
22(4):
1248 - 1255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tozzi, E. Guatteo, L. Caputi, G. Bernardi, and N. B. Mercuri
Group I mGluRs Coupled to G Proteins Are Regulated by Tyrosine Kinase in Dopamine Neurons of the Rat Midbrain
J Neurophysiol,
June 1, 2001;
85(6):
2490 - 2497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Williams, M. J. Christie, and O. Manzoni
Cellular and Synaptic Adaptations Mediating Opioid Dependence
Physiol Rev,
January 1, 2001;
81(1):
299 - 343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Koga and T. Momiyama
Presynaptic dopamine D2-like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones
J. Physiol.,
February 15, 2000;
523(1):
163 - 173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shoji, J. Delfs, and J. T. Williams
Presynaptic Inhibition of GABAB-Mediated Synaptic Potentials in the Ventral Tegmental Area during Morphine Withdrawal
J. Neurosci.,
March 15, 1999;
19(6):
2347 - 2355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Martin, R. Przewlocki, and G. R. Siggins
Chronic Morphine Treatment Selectively Augments Metabotropic Glutamate Receptor-Induced Inhibition of N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Nucleus Accumbens
J. Pharmacol. Exp. Ther.,
January 1, 1999;
288(1):
30 - 35.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. L. Ingram, C. W. Vaughan, E. E. Bagley, M. Connor, and M. J. Christie
Enhanced Opioid Efficacy in Opioid Dependence Is Caused by an Altered Signal Transduction Pathway
J. Neurosci.,
December 15, 1998;
18(24):
10269 - 10276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Numan, S. B. Lane-Ladd, L. Zhang, K. H. Lundgren, D. S. Russell, K. B. Seroogy, and E. J. Nestler
Differential Regulation of Neurotrophin and trk Receptor mRNAs in Catecholaminergic Nuclei during Chronic Opiate Treatment and Withdrawal
J. Neurosci.,
December 15, 1998;
18(24):
10700 - 10708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Chieng and J. T. Williams
Increased Opioid Inhibition of GABA Release in Nucleus Accumbens during Morphine Withdrawal
J. Neurosci.,
September 1, 1998;
18(17):
7033 - 7039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tao, Z. Ma, and S. B. Auerbach
Alteration in Regulation of Serotonin Release in Rat Dorsal Raphe Nucleus after Prolonged Exposure to Morphine
J. Pharmacol. Exp. Ther.,
July 1, 1998;
286(1):
481 - 488.
[Abstract]
[Full Text]
|
 |
|
|

|